A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival by Jia, Min et al.
RESEARCH Open Access
A prognostic CpG score derived from
epigenome-wide profiling of tumor tissue
was independently associated with
colorectal cancer survival
Min Jia1, Yan Zhang1, Lina Jansen1, Viola Walter1, Dominic Edelmann2, Melanie Gündert3,4, Katrin E. Tagscherer5,6,
Wilfried Roth5,6, Melanie Bewerunge-Hudler7, Esther Herpel5,8, Matthias Kloor9, Alexis Ulrich10, Barbara Burwinkel3,4,
Hendrik Bläker11, Jenny Chang-Claude12, Hermann Brenner1,13,14 and Michael Hoffmeister1*
Abstract
Background: Results of previous studies on the association of the CpG island methylator phenotype (CIMP) with
colorectal cancer (CRC) prognosis were inconsistent and mostly based on different CIMP definitions. The current
study aimed to comprehensively investigate the associations between DNA methylation on genes previously used
to define CIMP status with CRC survival.
Results: Patients with CRC followed up for a median of 5.2 years were divided into a study cohort (n = 568) and a
validation cohort (n = 308). DNA methylation was measured in tumor tissue using the Illumina Infinium
HumanMethylation450 BeadChip and restricted to 43 genes used to define CIMP status in previous studies. Cox
proportional hazard regression models were used to estimate adjusted hazard ratios (HR) and 95% confidence
intervals (CI) of survival after CRC, including adjustment for tumor stage, microsatellite instability, and BRAF
mutation status. In the study cohort, ten CpG sites were identified to be associated with CRC survival. Seven of
these ten CpG sites were also associated with CRC survival in the validation cohort and were used to construct a
prognostic score. CRC patients with a prognostic score of the lowest methylation level showed poorer disease-
specific survival compared with patients with the highest methylation level in both the study cohort and the
validation cohort (HR = 3.11 and 95% CI = 1.97–4.91, and HR = 3.06 and 95% CI = 1.71–5.45, respectively).
Conclusions: A CpG panel consisting of seven CpG sites was found to be strongly associated with CRC survival,
independent from important clinical factors and mutations associated with CIMP. Further studies are required to
confirm these findings.
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Background
Colorectal cancer (CRC) is one of the most common
cancers worldwide with a 5-year survival rate of more
than 60% [1]. Survival after CRC is largely dependent on
the disease stage at diagnosis, but there is accumulating
evidence that somatic mutations and epigenetic changes
play a significant role in the progression of CRC and
already guide clinical decision-making [2, 3]. As an im-
portant regulation approach in epigenetics, aberrant
DNA methylation was extensively observed in various
cancers including CRC. High-level methylation of CpG
islands in the promoter region (CpG island methylator
phenotype (CIMP)) can induce the silencing of the
tumor-suppressor genes, which can stimulate tumor on-
set and progression [4–6]. Colorectal tumors showing
such methylation were consistently associated with pa-
tient and tumor characteristics, such as older age,
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proximal location, and microsatellite instability (MSI-H)
[7]. However, studies on the association of CIMP status
and survival after CRC were inconsistent [8, 9]. In addition
to methodological issues in some of the studies, studies
mostly used different marker sets to define CIMP, which
likely contributed to the inconsistency of results [10, 11].
In previous studies, genes used to define CIMP status
were either selected because they were cancer suppressor
genes silenced by methylation in the promoter region or
because they were differentially methylated in tumor tis-
sue and normal tissue [5, 7, 12]. Although high methyla-
tion of CpG islands in the promoter region is presumed to
silence these genes, other aberrant methylations on these
genes may also influence their activity. Meanwhile, high-
throughput assays are available to comprehensively assess
methylation of CpGs on CIMP-related genes [13, 14]. We
therefore aimed to investigate the association between
methylation of CpG sites on genes previously used to
define CIMP status with CRC survival.
Results
Patient cohort
Of 702 patients in the study cohort and 366 patients in
the validation cohort, 134 patients and 58 patients, re-
spectively, were excluded because of missing information
on important covariates (chemotherapy, MSI status, or
BRAF mutation status). Finally, 568 patients in the study
cohort and 308 patients in the validation cohort were
included in the analyses. The median follow-up time was
5.2 years in both cohorts. The characteristics of the pa-
tients included in the study cohort and validation cohort
were very similar. Slight differences were observed in the
distribution of the education level, alcohol consumption,
lymph node count, chemotherapy frequency, and KRAS
mutation (Additional file 1: Table S1).
Selection of CIMP-related genes
The literature search yielded 48 genes that were used to
define CIMP in previous studies [15, 16]. Five of these
48 genes were not covered by the 450k methylation
array but were also rarely used for the definition of
CIMP (Additional file 1: Table S2). Within the 43 CIMP
genes investigated in this study, 405 CpGs were located
in CpG islands of the promoter region (CpG set 1), 701
CpGs were located in CpG islands of any region (CpG
set 2), and 1852 CpGs were located anywhere on the
genes (CpG set 3) (Fig. 1).
Identification of prognostic CpGs
In adjusted analyses, 42 CpGs from CpG set 1 and 65 CpGs
from CpG set 2 were found to be associated with disease-
specific survival (DSS) (p value<0.05). However, after cor-
rection for multiple testing, none of these CpG sites was
associated with DSS anymore. By further extension to
CpGs anywhere on the genes (CpG set 3), 10 of the 249 as-
sociated CpG sites showed significant associations with
DSS after correction for multiple testing.
Three of the 10 CpGs had β values with a range from the
10th to the 90th percentile of less than 0.1 which was
considered too narrow to define distinct groups
(cg05075097, cg24771017, and cg20537325). Two of the
three CpGs were also not associated with DSS in the
validation cohort (cg05075097 and cg24771017). There-
fore, seven CpGs (cg16935707, cg05481217, cg08044454,
cg01552551, cg24311416, cg02425108, and cg15659052)
confirmed in the validation cohort were included in the
final analyses (Fig. 1, Additional file 1: Table S3).
Associations of identified CpG sites with survival
All seven CpGs showed similar associations with DSS in
the study cohort and the validation cohort (Fig. 2, Add-
itional file 1: Figure S1). Compared to tertile group 3,
tertile group 1 (lowest methylation) showed significantly
poorer survival for all the seven CpGs in the study co-
hort. Very similar results were observed in the validation
cohort, except for cg02425108, where the association
was somewhat weaker (Table 1).
Associations of the prognostic methylation score with
survival
The coefficient values for the calculation of the coefficient
score were − 1.24524 for cg16935707, − 1.32717 for
cg05481217, − 1.23953 for cg08044454, − 1.15191 for
cg01552551, − 0.62350 for cg24311416, − 0.53487 for
cg02425108, and − 0.17845 for cg15659052. Using this
score based on methylation at seven CpG sites, low
methylation was strongly associated with poorer DSS
compared with high methylation in the study cohort
(HR = 3.16; 95% CI = 2.08–4.80) and in the validation co-
hort (HR = 2.75; 95% CI = 1.56–4.85) (Table 2). Patients
with intermediate methylation scores also showed poorer
DSS compared to patients with high methylation scores;
however, the trend was not statistically significant.
Unadjusted Kaplan–Meier curves of the association of
the prognostic score with DSS and non-DSS showed
poorer survival in the lowest tertile group only (survival
rates after 36 months were 68% and 87% for patients in
the lowest and highest tertile of the prognostic score, re-
spectively; Additional file 1: Figure S2). Using direct ad-
justed survival curves, the middle and lowest tertile
score were increasingly strongly associated with poorer
DSS, whereas no association was found for CRC patients
who died of other causes (Fig. 3). In addition, by adding
our CpG panel to the model constructed by the clinical
and molecular factors, the AIC decreased from 1461 to
1433 in the study cohort and from 823 to 812 in the
validation cohort. As most of the CRC patients died of
CRC, the association of the methylation panel with
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overall survival was similar with the association for DSS
(data not shown).
In subgroup analyses stratified by tumor location, MSI
status, and BRAF mutation status, similar results were ob-
served for the association between the prognostic scores
and DSS (Table 2). The prognostic score was not related to
clinical and tumor characteristics of the CRC patients such
as age, sex, education level, family history of CRC, lifetime
regular active smoking status, tumor location, cancer stage,
lymph node count, chemotherapy, KRAS mutation, BRAF
mutation, and MSI status in both study and validation co-
hort. Only for chemotherapy heterogeneity was observed in
the study cohort due to dissimilar distribution in the tertile
3 group. However, this was not observed in the validation
cohort (Additional file 1: Table S4).
Discussion
In this population-based patient cohort study, we identi-
fied seven CpG sites on 43 genes previously used to
define CIMP status in the published literature that were
independently associated with DSS. At each of the seven
CpG sites, lower methylation levels were strongly associ-
ated with poorer survival after CRC. The associations
observed in the study cohort and the validation cohort
were very similar, suggesting that results might be repro-
ducible in other cohorts, too. By incorporating the seven
Fig. 1 Flow chart of CIMP-related gene selection and identification of prognostic CpG sites associated with disease-specific survival. Cox
regression analyses adjusted for age, sex, tumor location, tumor stage, chemotherapy, BRAF mutation, and microsatellite instability
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Fig. 2 Dose-response association of methylation levels and disease-specific survival in the study cohort and the validation cohort. Restricted cubic
splines analyses with adjustment for age, sex, tumor location, tumor stage, chemotherapy, BRAF, mutation and microsatellite instability
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CpGs into a prognostic CpG score we constructed a po-
tential prediction panel for CRC prognosis.
As one of the most widely investigated features of
CRC, CIMP was inconsistently associated with poorer
outcome in previous studies and the CIMP definitions
used were largely different [8, 17]. Mostly, studies fo-
cused on CpG sites in the promoter region, where
hypermethylation is the aberrant type in cancer cells. In
the present study, all seven identified CpGs were se-
lected from CIMP-related genes which we assumed was
a more effective approach compared to an epigenome-
wide analysis. Recently, a genome-wide methylation
study reported a prognostic classifier for non-metastatic
CRC consisting of 20 CpGs which also showed poorer
survival with lower levels of methylation at the associ-
ated CpG sites [18]. The identified CpGs in our study
did not overlap, and our score showed a slightly stronger
prognostic effect. Among the seven prognostic CpGs
identified, cg16935707, cg05481217, and cg24311416 are
located in the gene bodies, cg08044454 and cg15659052
are located in the 5′UTR region, cg02425108 is located
in the 3′UTR region, and only cg01552551 is located in
the S-shore of a CpG island which belongs to the pro-
moter region. At all seven CpG sites, lower methylation
instead of higher methylation was associated with poorer
survival. Although the molecular mechanism of the as-
sociation between hypomethylation of CpGs and poorer
CRC survival is not known, methylation in the gene
Table 1 Association of methylation at the seven identified CpG sites with disease-specific survival in the study cohort and the
validation cohort
CpG sites Methylation level Study cohort Validation cohort
N Deaths (%) HR (95% CI)a p value of trend N Deaths (%) HR (95% CI)a p value of trend
cg16935707 β valueb 568 1.43 (1.22–1.67) < 0.0001 308 1.33 (1.09–1.61) 0.0046
Tertile 3 193 45 (23) Ref. 125 27 (22) Ref.
Tertile 2 (0.84342) 182 38 (21) 1.53 (0.98–2.39) 99 25 (25) 1.95 (1.08–3.52)
Tertile 1 (0.72736) 193 53 (27) 2.22 (1.46–3.36) 0.0002 84 30 (36) 2.12 (1.20–3.74) 0.0095
cg05481217 β valueb 568 1.43 (1.22–1.67) < 0.0001 308 1.30 (1.06–1.60) 0.0115
Tertile 3 187 36 (19) Ref. 173 42 (24) Ref.
Tertile 2 (0.66890) 183 36 (20) 1.29 (0.79–2.08) 78 17 (22) 1.27 (0.71–2.27)
Tertile 1 (0.61265) 198 64 (32) 2.23 (1.46–3.42) 0.0002 57 23 (40) 2.02 (1.18–3.45) 0.0125
cg08044454 β valueb 568 1.44 (1.22–1.69) < 0.0001 308 1.39 (1.14–1.70) 0.0014
Tertile 3 195 40 (21) Ref. 110 20 (18) Ref.
Tertile 2 (0.71507) 195 41 (21) 1.25 (0.80–1.97) 98 28 (29) 1.87 (1.03–3.42)
Tertile 1 (0.57145) 178 55 (31) 2.23 (1.44–3.46) 0.0003 100 34 (34) 2.48 (1.39–4.44) 0.0021
cg01552551 β valueb 568 1.43 (1.22–1.68) < 0.0001 308 1.28 (1.04–1.58) 0.0215
Tertile 3 189 28 (15) Ref. 104 25 (24) Ref.
Tertile 2 (0.72226) 189 49 (26) 1.94 (1.21–3.10) 95 22 (23) 1.38 (0.76–2.51)
Tertile 1 (0.59834) 190 59 (31) 2.50 (1.58–3.95) < 0.0001 109 35 (32) 2.17 (1.24–3.79) 0.0065
cg24311416 β valueb 568 1.43 (1.21–1.71) < 0.0001 308 1.32 (1.04–1.66) 0.0209
Tertile 3 190 40 (21) Ref. 118 27 (23) Ref.
Tertile 2 (0.65694) 185 38 (21) 1.03 (0.64–1.64) 90 23 (26) 1.06 (0.59–1.89)
Tertile 1 (0.53430) 193 58 (30) 2.20 (1.45–3.35) 0.0002 100 32 (32) 2.00 (1.17–3.43) 0.0135
cg02425108 β valueb 568 1.40 (1.19–1.65) < 0.0001 308 1.32 (1.04–1.66) 0.0200
Tertile 3 209 35 (17) Ref. 104 27 (26) Ref.
Tertile 2 (0.62299) 175 38 (22) 1.78 (1.12–2.85) 107 28 (26) 1.32 (0.75–2.31)
Tertile 1 (0.52523) 184 63 (34) 2.44 (1.59–3.74) < 0.0001 97 27 (28) 1.68 (0.95–2.96) 0.0727
cg15659052 β valueb 568 1.38 (1.17–1.63) 0.0001 308 1.37 (1.09–1.71) 0.0062
Tertile 3 183 30 (16) Ref. 113 25 (22) Ref.
Tertile 2 (0.53788) 193 38 (20) 2.12 (1.28–3.51) 92 17 (18) 1.55 (0.80–2.99)
Tertile 1 (0.40182) 192 68 (35) 2.34 (1.50–3.67) 0.0002 103 40 (39) 1.99 (1.16–3.34) 0.0118
Abbreviations: HR hazard ratio, CI confidence interval
aCox regression analyses adjusted for age, sex, tumor stage, tumor location, chemotherapy, MSI status, and BRAF mutation status
bHR calculated for per unit decrease of the Z score of the β values
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Table 2 Association of the coefficient score with disease-specific survival in the study cohort and the validation cohort
Patient groups Subgroups Tertile groups
(cutoff points)
Study cohort Validation cohort
N Deaths (%) HR (95% CI)a p value
of trend
N Deaths (%) HR (95% CI)a p value
of trend
All patients Tertile 3 195 36 (18) Ref. 124 25 (20) Ref.
Tertile 2 (− 4.32247) 188 31 (16) 1.31 (0.80–2.15) 89 22 (25) 1.66 (0.91–3.05)
Tertile 1 (− 3.92950) 185 69 (37) 3.16 (2.08–4.80) < 0.0001 95 35 (37) 2.75 (1.56–4.85) 0.0004
Microsatellite
instability
MSS Tertile 3 175 35 (20) Ref. 114 25 (22) Ref.
Tertile 2 (− 4.32247) 161 29 (18) 1.31 (0.79–2.17) 79 21 (27) 1.63 (0.88–3.01)
Tertile 1 (− 3.92950) 167 66 (40) 3.11 (2.04–4.76) < 0.0001 89 33 (37) 2.65 (1.49–4.72) 0.0009
MSI-H Tertile 3 20 1 (5) Ref. 10 0 (0) Ref.
Tertile 2 (− 4.32247) 27 2 (7) NC 10 1 (10) NC
Tertile 1 (− 3.92950) 18 3 (17) NC NC 6 2 (33) NC NC
BRAF mutation Negative Tertile 3 185 34 (18) Ref. 115 22 (19) Ref.
Tertile 2 (− 4.32247) 171 28 (16) 1.23 (0.74–2.07) 81 19 (23) 1.53 (0.81–2.91)
Tertile 1 (− 3.92950) 166 61 (37) 3.24 (2.09–5.02) < 0.0001 93 34 (37) 2.72 (1.53–4.85) 0.0007
Positive Tertile 3 10 2 (20) Ref. 9 3 (33) Ref.
Tertile 2 (− 4.32247) 17 3 (18) NC 8 3 (38) NC
Tertile 1 (− 3.92950) 19 8 (42) NC NC 2 1 (50) NC NC
Tumor location Proximal
colon
Tertile 3 59 5 (8) Ref. 40 10 (25) Ref.
Tertile 2 (− 4.32247) 80 11 (14) 2.60 (0.87–7.84) 27 6 (22) 0.99 (0.31–3.13)
Tertile 1 (− 3.92950) 71 25 (35) 6.92 (2.46–19.4) < 0.0001 41 14 (34) 2.05 (0.79–5.34) 0.1176
Distal colon Tertile 3 71 19 (27) Ref. 41 5 (12) Ref.
Tertile 2 (− 4.32247) 49 5 (10) 0.73 (0.25–2.14) 26 8 (31) 1.76 (0.51–6.09)
Tertile 1 (− 3.92950) 56 20 (36) 2.03 (1.05–3.94) 0.0477 21 8 (38) 6.00 (1.61–22.4) 0.0098
Rectum
proximal
Tertile 3 65 12 (18) Ref. 43 10 (23) Ref.
Tertile 2 (− 4.32247) 59 15 (25) 1.36 (0.62–3.01) 36 8 (22) 3.48 (0.97–12.4)
Tertile 1 (− 3.92950) 58 24 (41) 3.59 (1.64–7.87) 0.0012 33 13 (39) 4.02 (1.38–11.7) 0.0129
Abbreviations: CI confidence interval, HR hazard ratio, NC not calculated (< 5 patients)
aCox regression adjusted for age, sex, tumor stage, tumor location, chemotherapy, MSI status, and BRAF mutation status
Fig. 3 Direct survival curves of the coefficient score with disease-specific survival and non-disease-specific survival in the validation cohort
(adjusted for age, sex, tumor location, tumor stage, chemotherapy, BRAF mutation, and microsatellite instability)
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body, where hypomethylation is the aberrant type, was
found to contribute to cancer-causing somatic and
germline mutations in previous studies [19, 20]. In a
study on primary glioblastoma, Nagarajan et al. found
recurring gene body promoter hypomethylation events
which may alter the transcriptional landscape of glio-
blastoma through the activation of a limited number
of normally silenced promoters within gene bodies, in
at least one case leading to expression of an onco-
genic protein [21].
The seven identified CpGs are located on three
different genes: ELMO1 (cg05481217, cg08044454,
cg01552552, and cg15659052), CADM1 (cg16935707
and cg24311416), and ADAMTS1 (cg02425108).
ELMO1 (engulfment and cell motility 1) together
with Dock180 as a complex plays an important role
in promoting cancer cell invasion which has been
shown for gliomas, breast cancer, and ovarian cancer
[22–24]. Methylation markers on ELMO1 were re-
ported to be associated with cancers such as oropha-
ryngeal squamous cell carcinoma and glioblastoma.
One other smaller study which adjusted for mucin-
ous type and location only investigated methylation
in ELMO1 along with other epigenetic markers in a
panel and found worse prognosis in KRAS mutated
cancers [25–27]. Cell adhesion molecule 1 (CADM1/
TSLC1) is a putative tumor suppressor involved in
cell adhesion, proliferation, and apoptosis [28, 29].
The epigenetic inactivation of CADM1/TSLC1 was
found as a frequent alteration in the development of
CRC and correlates with late stages of the disease [30].
ADAMTS1 (a disintegrin and metalloproteinase with
thrombospondin type 1 motifs) is an extracellular
matrix metalloproteinase with protease activity and
antiangiogenic activity [31]. ADAMTS1 was identified
as an epigenetically deregulated gene in CRC, and it
was suggested that ADAMTS1 could play an import-
ant role in tumor growth and metastasis [32]. All three
genes involved are tumor suppressor genes that seem
to have effects on tumor growth and metastasis. The
alteration of methylation of these genes may play an
important role in tumor progression and in the prog-
nosis of CRC patients.
To our knowledge, this is the first study that compre-
hensively investigates the association between methyla-
tion of CpG sites on CIMP-related genes and CRC
prognosis in a large patient cohort which is not re-
stricted to specific gene regions. Besides DNA methyla-
tion, other molecular pathological features such as MSI,
BRAF mutation, and single-nucleotide polymorphisms
(SNPs) were frequently investigated for their prognostic
value in CRC. For example, MSI-H was found to be a
marker of better prognosis among CRC patients in a
meta-analysis (OR = 0.58; 95% CI 0.47–0.72), and
patients with BRAF mutation were found to have signifi-
cantly worse progression-free survival compared with
BRAF wild-type patients (HR = 1.33; 95% CI 1.12–1.57)
[33, 34]. However, as the prognostic values of MSI and
BRAF mutation seem to be affected by each other, it was
suggested that these markers should be considered
jointly [35]. A genome-wide analysis of SNPs illustrated
that several SNPs were statistically associated with
poorer survival of CRC, with the strongest associations
noted for rs209489 (HR = 1.8, p = 7.6 × 10−10). However,
this result has not been validated in an independent co-
hort yet [36]. Compared with these biomarkers, all the
seven prognostic CpGs were selected through multivari-
able Cox regression with adjustment considering tumor
stage, MSI status, and BRAF mutation status as con-
founders. As validation in an independent cohort yielded
very similar results, the panel might be a tool for outcome
prediction but further validation in large studies is needed.
Besides outcome prediction, further studies will be needed
to investigate if and to what extent the CpG score is also
useful for the prediction of therapy response.
Both the study cohort and validation cohort were de-
rived from a large population-based study including 876
unselected patients with complete information on clin-
ical and molecular characteristics. Despite the adequate
size of the cohort population, the statistical power was
still limited in many of the subgroup analyses. Also, the
prognostic CpGs identified were selected from CIMP-re-
lated genes. It is likely that CpGs of other genes could
also be associated with CRC survival, and incorporating
these additional sites may further improve the prognos-
tic use of our panel. Accordingly, more large studies on
the association between methylation of CpG sites and
CRC outcomes are needed without restrictions to spe-
cific gene regions. Also, although the CpG sites were
confirmed and similarly associated in the validation co-
hort, external validation in another study is still needed
to establish the prognostic score.
Conclusion
In summary, our study found that DNA methylations at
seven CpG sites on CIMP-related genes were strongly
associated with CRC prognosis independent of cancer
stage, MSI status, BRAF mutation status, and other
important factors that affect the outcome of CRC. The
prognostic score based on methylation levels at these
seven CpG sites strongly predicted CRC survival in the
study cohort and the validation cohort. If confirmed in
other cohorts, this CpG panel could be a novel tool for
CRC outcome prediction and may have relevance for
clinical decision-making. Still, other large studies are
needed to confirm our findings and to elaborate its
potential utility.
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Methods
Study population
Patients with CRC were recruited into the DACHS
(Darmkrebs: Chancen der Verhütung durch Screening)
study, a large ongoing population-based cohort study on
CRC with long-term follow-up [37]. Patients histologi-
cally confirmed CRC who were at least 30 years old and
physically and mentally able to participate in a personal
interview were enrolled in 22 hospitals in the Rhine–
Neckar–Odenwald region of southwestern Germany.
Sociodemographic and lifestyle information was col-
lected by trained interviewers using a standardized ques-
tionnaire during face-to-face interviews. Additionally,
discharge letters, pathology reports, and endoscopy
reports were collected at baseline. After 3 years, informa-
tion on the patients’ therapy was requested from the pa-
tients’ physicians. After 5 years, survivors were contacted
to complete a standardized questionnaire. In addition, at
both follow-ups, disease recurrence was assessed. Also,
data on vital status were obtained from the population
registries and causes of death were verified by death cer-
tificates from the health authorities. More details on the
study design, data collection, and follow-up have been
reported previously [38, 39].
In the present study, only patients recruited between
2003 and 2007 with available information on DNA
methylation were included. The study was approved by
the ethics committees of the Medical Faculty of the Uni-
versity of Heidelberg and of the Medical Chambers of
Baden–Wuerttemberg and Rhineland–Palatinate.
Tumor sample analyses
DNA was extracted from formalin-fixed, paraffin-em-
bedded (FFPE) tumor samples of the patients under
microscopic control of unstained slides and was pre-
pared using the DNeasy tissue kit (Qiagen, Hilden,
Germany) [40]. Methylation of tissue DNA was ana-
lyzed using the Illumina Human Methylation 450 Bead-
Chip (Illumina, San Diego, CA, USA) following the
manufacturer’s instructions. Tumors of patients examined
in the pathology institutes in Heilbronn, Ludwigshafen,
Mannheim, and Speyer (study cohort) were analyzed more
than 1 year apart from tumors of patients examined
in the pathology institute in Heidelberg (validation
cohort). Methylation signals at CpG sites were con-
verted into β values (methylated signal/(unmethylated
signal + methylated signal)). β values ranged from 0
to 1: 0 represents totally unmethylated and 1 repre-
sents totally methylated. In data pre-processing, the
following probes were excluded: probes targeting the X and
Y chromosomes, probes containing a single-nucleotide
polymorphism (dbSNP132 Common) within five base pairs,
probes not mapping uniquely to the human reference gen-
ome (hg19) allowing for one mismatch, and probes that
have failed in more than 10% of the samples based on the
detection p value (detection p value > 0.01). Data was nor-
malized by pre-processing in the R package “minfi” [41].
MSI status was determined using a mononucleotide
marker panel (BAT25, BAT26, and CAT25) [42]. KRAS
mutation was determined by single-stranded conform-
ational polymorphism technique using the same DNA
sample [43]. The expression of BRAF V600E was
determined by immunohistochemical analyses in sec-
tions of tissue microarray blocks and evaluated by
two pathologists independently.
Statistical analysis
Genes used to define CIMP in previous studies were
identified by a literature review [15, 16]. We focused on
CIMP genes because CIMP is an established marker in
CRC to differentiate between CRC pathways. We as-
sumed that methylation on these genes could be more
relevant than on other genes when investigating associa-
tions with survival. Also, by focusing on CIMP genes,
the number of association tests is lower which increases
the chance to find associations even after adjustment for
multiple testing.
In a split-sample approach, we used a larger study co-
hort to investigate associations of CpG sites on CIMP-
related genes with DSS and a smaller validation cohort
to validate our findings. Hazard ratios (HR) and 95%
confidence intervals (95% CI) were calculated by multi-
variable Cox proportional hazard regression with adjust-
ment for age, sex, tumor stage, tumor location,
chemotherapy, MSI status, and BRAF mutation status.
In addition, a correction for late entry defined as the po-
tentially delayed time between the date of diagnosis and
the date of enrolment was included in the adjusted
model, as well as a time-dependent variable of age and
chemotherapy. We used three different sets of CpGs on
the CIMP genes to test for associations: CpG set 1 con-
sisted of CpGs located in the CpG islands of promoter
regions, CpG set 2 included any CpG in CpG islands,
and CpG set 3 included any CpG in any region on the
genes (Fig. 1). In the study cohort, CpGs were deemed
to be associated with CRC prognosis only if they passed
the correction for multiple testing by Benjamini–Hoch-
berg (false discovery rates (FDR) < 0.05) and if the β
value range was not too narrow (≥ 0.1) to ensure
reproducibility.
The CpGs associated with DSS in the study cohort
were then analyzed in the validation cohort using the
same adjusted Cox model. The association between ter-
tiles of β values and DSS analyzed in the study cohort
was analyzed in the validation cohort using the tertile
cutoffs of the study cohort. Dose-response curves of
methylation levels at the identified CpGs were plotted to
illustrate the association with DSS by restricted cubic
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spline regression adjusting for the confounders men-
tioned above. The CpGs confirmed in the validation co-
hort were used to investigate individual associations and
to construct a prognostic score using the coefficient
score. A heatmap illustrating the methylation level of
the selected CpGs and their association with CRC sur-
vival was generated using the R package “pheatmap”.
The coefficient score was calculated by summing the
product of the β value of each validated CpG with its
corresponding coefficient value in the Cox regression.
Tertiles of the sum were used to build three groups with
tertile 3 representing patients with the highest methyla-
tion at the selected CpGs sites, which was used as the
reference (among the identified CpGs, lower methylation
was associated with higher mortality). The coefficient
value and tertile cutoff point identified in the study co-
hort were used for the analyses in the validation cohort.
Direct adjusted survival curves (adjusting for the same
covariates) and Kaplan–Meier curves were plotted to il-
lustrate the association of the prognostic score with DSS
and non-DSS (deaths due to other causes) over time.
The associations of clinical and molecular features with
the coefficient score in the study and the validation co-
hort were analyzed by chi-square test. The Akaike infor-
mation criterion (AIC) was computed using R, software
version 3.5.0. All other statistical analyses were per-
formed with SAS, software version 9.4 (SAS Institute
Inc., Cary, NC, USA).
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